Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation

NCT02960646 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02960646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02960646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
January 18, 2017
Completion date
February 13, 2023
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, aplastic anemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, chronic myelomonocytic leukemia, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, lymphoblastic lymphoma, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell myeloma, recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma, recurrent hodgkin lymphoma, recurrent non-hodgkin lymphoma, recurrent plasma cell myeloma, therapy-related myelodysplastic syndrome